210 related articles for article (PubMed ID: 9815539)
1. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.
Hauck ML; Dewhirst MW; Bigner DD; Zalutsky MR
Clin Cancer Res; 1997 Jan; 3(1):63-70. PubMed ID: 9815539
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
[TBL] [Abstract][Full Text] [Related]
3. The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.
Hauck ML; Zalutsky MR
Clin Cancer Res; 1998 Sep; 4(9):2071-7. PubMed ID: 9748121
[TBL] [Abstract][Full Text] [Related]
4. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.
Cope DA; Dewhirst MW; Friedman HS; Bigner DD; Zalutsky MR
Cancer Res; 1990 Mar; 50(6):1803-9. PubMed ID: 2407344
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):13-27. PubMed ID: 15764348
[TBL] [Abstract][Full Text] [Related]
6. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
7. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.
De Santis R; Albertoni C; Petronzelli F; Campo S; D'Alessio V; Rosi A; Anastasi AM; Lindstedt R; Caroni N; Arseni B; Chiodi P; Verdoliva A; Cassani G; Chinol M; Paganelli G; Carminati P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2191-6. PubMed ID: 16609034
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
[TBL] [Abstract][Full Text] [Related]
10. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Reist CJ; Bigner DD; Zalutsky MR
Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
[TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Schuster JM; Garg PK; Bigner DD; Zalutsky MR
Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
[TBL] [Abstract][Full Text] [Related]
12. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
Boskovitz A; Akabani GH; Pegram CN; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Apr; 31(3):345-55. PubMed ID: 15028247
[TBL] [Abstract][Full Text] [Related]
13. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
14. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
15. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
16. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts.
Ward BG; Wallace K
Cancer Res; 1987 Sep; 47(17):4714-8. PubMed ID: 3621167
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
[TBL] [Abstract][Full Text] [Related]
18. [Radioimmunodetection of 188Re-labeled anti-carcinoembryonic antigen chimeric antibody in nude mice bearing human colon carcinoma].
Zhao ZG; Ran YL; Zheng R; Kong J; Chen SZ; Yu L; Yang ZH
Ai Zheng; 2002 May; 21(5):460-3. PubMed ID: 12452032
[TBL] [Abstract][Full Text] [Related]
19. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation.
Kalofonos H; Rowlinson G; Epenetos AA
Cancer Res; 1990 Jan; 50(1):159-63. PubMed ID: 2403414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
